CGP-39551
Competitive NMDA receptor antagonist
From Wikipedia, the free encyclopedia
CGP-39551 is a drug used in scientific research, it is investigated as an anti-convulsant.[2]
| |
| Names | |
|---|---|
| IUPAC name
[(E)-4-amino-5-ethoxy-2-methyl-5-oxopent-2-enyl]phosphonic acid | |
| Identifiers | |
3D model (JSmol) |
|
| ChemSpider | |
| EC Number |
|
PubChem CID |
|
| |
| |
| Properties | |
| C8H16NO5P | |
| Molar mass | 237.192 g·mol−1 |
| Hazards | |
| GHS labelling:[1] | |
 | |
| Danger | |
| H301 | |
| P264, P270, P301+P316, P321, P330, P405, P501 | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Mechanism of action
CGP-39551 and some related molecules are competitive antagonists of the N-methyl D-aspartate receptor, an excitatory receptor activated by glutamate.[3][4]
Potential
As other glutamate antagonists, CGP-39551 possesses anti-convulsant properties. It is able to suppress seizures caused by electroshock, with a duration of action superior to 24 hours.[5]
It has also been shown to be able to block convulsions caused by vestibular stimulation.[6]
Additionally, CGP-39551 appears to be better than some other NMDA blockers in terms of side effects, since the dose required for its anti-convulsant action does not have significant impact on memory and learning, unlike certain drugs with a similar mechanism of action such as Dizocilpine.[7]